• Kristyna Zarubova, Ondrej Hradsky, Ivana Copova, Blanka Rouskova, Lucie Pos, Richard Skaba, and Jiri Bronsky.
• *Gastroenterology, Hepatology and Nutrition Unit, Department of Pediatrics †Department of Pediatric Surgery, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
• J. Pediatr. Gastroenterol. Nutr. 2017 Aug 1; 65 (2): 207-211.

ObjectivesIntestinal surgery is an important part of Crohn disease (CD) treatment in children. The aim of the present study was to compare the rate of endoscopic recurrence at the sixth month after ileocecal resection (ICR) in children with CD treated with azathioprine between patients who received prior antitumor necrosis factor alpha (anti-TNF-α) therapy and those who were not administered this therapy. Moreover, we tried to identify the potential risk factors for disease recurrence and describe the schedule of long-term follow-up after surgery.MethodsWe prospectively collected data from pediatric patients with CD, who underwent ICR between October 2011 and June 2015 at our hospital and were treated with azathioprine monotherapy after ICR. We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients.ResultsAmong 21 included patients, 13 achieved endoscopic remission (Rutgeerts score < i2) at the sixth month after ICR. No difference was found between patients who received prior anti-TNF-α therapy and those who did not. We did not find any clinically relevant factors associated with endoscopic recurrence rate at the sixth month.ConclusionsPrior anti-TNF-α therapy does not seem to be a strong risk factor for endoscopic recurrence within 6 months after ICR. Further studies on large sample of patients are needed to identify potential predictors of disease recurrence.

34 keywords...

hide…